Giovanna Lôbo

Ms. Giovanna Lôbo

University of Brasilia (UnB)
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Giovanna LôboGiovanna Lôbo
Giovanna Lôbo
KPKaren Letycia Rodrigues de Paiva
Karen Letycia Rodrigues de Paiva
ASAna Luísa Silva
Ana Luísa Silva
MSMarina Mesquita Simões
Marina Mesquita Simões
MRMarina Arantes Radicchi
Marina Arantes Radicchi
SBSônia Báo
Sônia Báo
Cancer, a group of diseases responsible for the second largest cause of global death, is considered one of the main public health problems today. Despite the advances, there are still difficulties in the development of more efficient cancer therapies and fewer adverse effects for the patients. In this context, nanobiotechnology, a materials science on a nanometric scale specified for biology, has been developing and acquiring prominence for the synthesis of nanocarriers that provide a wide surface area in relation to volume, better drug delivery, and a maximization of therapeutic efficiency. Among these carriers, the ones that stand out are those focused on the activation of the immune system. The literature demonstrates the importance of this system for anticancer therapy, given that the best treatment for this disease also activates the immune system to recognize, track, and destroy all remaining tumor cells.